guest ::
| Home > Articles > Published articles > A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART |
| Home > Articles > Published articles > A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART |
(Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) (Institució Catalana de Recerca i Estudis Avançats) (Hospital Clínic i Provincial de Barcelona)| Date: | 2015 |
| Abstract: | TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo,followed by interruption of HAART. METHODS: The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. RESULTS: MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. CONCLUSION: MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity. TRIAL REGISTRATION: ClinicalTrials. gov NCT01571466. |
| Grants: | Ministerio de Ciencia e Innovación SAF2008-02036 Ministerio de Economía y Competitividad SAF2012-39075 Ministerio de Economía y Competitividad RD12-0017-0037 Ministerio de Economía y Competitividad RD12-0017-0038 |
| Note: | Altres ajuts: This work was supported by the Spanish government (SAF2008-02036, FIPSE-360731/09, SAF2012-39075, EC10-153, TRA-094, FIS PS09/01297), Red SIDA (RD12-0017-0037 and RD12-0017-0038) and the HIVACAT program. |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Published in: | PloS one, Vol. 10 Núm. 11 (november 2015) , ISSN 1932-6203 |
